Andromeda Surgical

andromedasurgical.com →

-91%

est. 2Y upside i

HealthcareSeed

Autonomous surgical robots

Rank

#2771

Sector

Surgical Robotics / Medical Devices

Est. Liquidity

~6Y

Data Quality

Data: Medium

Andromeda Surgical operates in a high-growth surgical robotics market with a large TAM, leveraging AI for enhanced surgical precision.

Last updated: March 10, 2026

Bull (15%)+400%

Andromeda Surgical achieves rapid FDA clearance for its HoLEP system and expands strategic partnerships (e.g., Richard Wolf, Quanta System), gaining significant traction in the endourology market. Its proprietary AI-guided software proves to be a strong differentiator, enabling superior outcomes and faster adoption. The company successfully raises a large Series A at a significantly higher valuation, reaching $150M (5x current valuation) by year 2.

Base (30%)+50%

Andromeda Surgical continues to develop its technology and secures initial commercial adoption in endourology. While facing strong competition from incumbents like PROCEPT BioRobotics and Medtronic, it carves out a niche with its AI-driven approach. Growth is steady but not explosive, leading to a Series A round that values the company at $45M (1.5x current valuation) within two years.

Bear (55%)-80%

Incumbents rapidly integrate similar AI capabilities, and slower-than-expected clinical adoption leads to a down round or a flat exit. With $6M in liquidation preferences, common stock holders receive minimal to no return, valuing the company at $6M (-80% from current valuation).

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $6M in liquidation preferences ahead of common stock, representing 20% of the estimated $30M current valuation.

Dilution Risk

high

As a seed-stage company, Andromeda Surgical will likely require multiple future funding rounds, leading to significant dilution for early common stock holders.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for a seed-stage company like Andromeda Surgical.

Questions to Ask at the Interview

Strategic questions based on Andromeda Surgical's data — designed to show you've done your homework.

  • 1

    “How is Andromeda Surgical planning to differentiate its AI-guided platform and secure market share against established competitors like PROCEPT BioRobotics and Medtronic's Hugo RAS, especially given their existing presence in urology and recent FDA clearances?”

  • 2

    “With a current revenue of ~$2M, what is the detailed go-to-market strategy and projected revenue growth trajectory over the next 2-3 years, particularly considering the high capital intensity and regulatory hurdles in the medical device sector?”

  • 3

    “Given the Seed funding stage and the need for future capital, how does the company envision the timeline for a liquidity event (e.g., IPO or acquisition) for employees, and what measures are in place to mitigate potential dilution from subsequent funding rounds?”

Community

Valuation Sentiment

Our model estimates -91% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.